DavidFrancisMcDermottMD

Associate Professor, Medicine, Harvard Medical School; Staff Physician, Hematology/Oncology, Beth Israel Deaconess Medical Center; Director, Biologic Therapy and Cutaneous Oncology Programs, Hematology/Oncology, Beth Israel Deaconess Medical Center

Join to view full profile

Dr. McDermott is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. McDermott's full profile

Already have an account?

Office
330 Brookline Ave
Boston, MA 02215
Phone+1 617-667-2100

Education & Training

Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1995 - 1998
Tufts Medical CenterResidency, Internal Medicine, 1992 - 1995
Weill Cornell MedicineClass of 1992

Certifications & Licensure

MA State Medical License 1998 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Paclitaxel and Carboplatin in Treating Patients With Locally Advanced or Metastatic Renal Cell Cancer Start of enrollment: 2006 Jun 01
Completed
Phase 2
Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2007 Sep 14
Completed
Phase 2
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders Start of enrollment: 2002 Dec 01
Completed
Phase 2
The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2006 Nov 01
Completed
Phase 2
Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders Start of enrollment: 1999 Jul 01
Completed
Phase 2
Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma Start of enrollment: 2009 Jan 23
Completed
Phase 2
Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma Start of enrollment: 2009 Mar 01
Completed
Phase 2
Mini Allo Stem Cell Transplantation for the Treatment of Solid Tumors Start of enrollment: 2000 Nov 01
Completed
Not Applicable
STA-9090(Ganetespib) in Metastatic Ocular Melanoma Start of enrollment: 2010 Sep 17
Completed
Phase 2
IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma Start of enrollment: 2010 Feb 01
Completed
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy Start of enrollment: 2011 Aug 01
Completed
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma Start of enrollment: 2013 Aug 01
Terminated
Phase 2
Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma Start of enrollment: 2013 Jan 01
Terminated
Phase 2
Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma Start of enrollment: 2013 Mar 08
Terminated
Phase 1, Phase 2
Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma Start of enrollment: 2014 May 01
Completed
Phase 1
High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery Start of enrollment: 2014 Nov 26
Terminated
Phase 2
Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Start of enrollment: 2016 Jul 01
Active, not recruiting
Phase 2
Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2016 Aug 01
Terminated
Phase 1, Phase 2
Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma Start of enrollment: 2017 Aug 01
Completed
Phase 2
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma Start of enrollment: 2017 Nov 27
Active, not recruiting
Phase 2
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC Start of enrollment: 2020 Nov 05
Recruiting
Phase 2
ABEMA Alone or in COMBO With MK-6482 Start of enrollment: 2020 Dec 31
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

2191 citations
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guide...
Julie R. Brahmer, Christina Lacchetti, Bryan J. Schneider, Michael B. Atkins, Kelly J. Brassil
Journal of Clinical Oncology. 2018-02-14
582 citations
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
David F. McDermott, Meredith M. Regan, Joseph I. Clark, Lawrence E. Flaherty, Geoffery R. Weiss
Journal of Clinical Oncology. 2005-01-01
9288 citations
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott N. Gettinger, David Smith
The New England Journal of Medicine. 2012-06-27

Journal Articles

Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell Carcinoma
Praful Ravi, Charlene Mantia, Christopher Su, Neeraj Agarwal, Yousef Zakharia, Rana R Mckay, Vivek Narayan, Ajjai Alva, Bradley A Mcgregor, David F Mcdermott, Toni K C..., JAMA Oncology
Publisher Correction: Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Ca...
Michael B Atkins, Mario Sznol, Robert J Motzer, Richard W Joseph, Thomas Hutson, John Hainsworth, W Kimryn Rathmell, Brian I Rini, David F McDermott, Toni K Choueiri, ..., Nature
Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Carcinoma
Michael B Atkins, Thomas Hutson, Mario Sznol, Toni K Choueiri, Sumanta K Pal, Richard W Joseph, John Hainsworth, W Kimryn Rathmell, David F McDermott, Robert J Motzer,..., Nature

Lectures

CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcino...
2019 ASCO Annual Meeting - 6/1/2019
Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Authored Content

Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020
Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020

Press Mentions

Researchers Discuss Future of Cancer Therapies at 15th Annual Cancer SymposiumNovember 11th, 2022
Researchers Discuss the Future of Cancer Therapies at 15th Annual Cancer SymposiumNovember 10th, 2022
Next-Generation Immunotherapy Drug Shows Continued Promise in Several Advanced-Stage CancersMay 26th, 2022
Join now to see all